Survival benefit in primary human IDH2-mutated AML xenograft mice compared to mice treated with cytarabine was dose-dependent, associated with reduction in R-2-HG, providing strong rationale for a phase I/II clinical trials (46). Here, IDH2 is linked to acute myeloid leukemia.